Is it time to add NAMENDA XR?
If your loved one is taking an AChEI for moderate to severe Alzheimer's disease
and symptoms are still getting worse, adding NAMENDA XR may help. Once your loved
one is diagnosed, it's important to monitor for any symptom changes, and report those changes
to your loved one's doctor. A progression of symptoms may indicate that it's time to start treatment.
People with moderate to severe Alzheimer's disease may benefit from combination therapy with
NAMENDA XR® (memantine HCl) and an AChEI.
How does Alzheimer's disease progress?
The disease progresses at different rates in different people. Generally, patients
with moderate Alzheimer's disease experience the fastest rate of decline. As a caregiver,
you know the person you're caring for better than anyone. Tell the healthcare provider
if you notice any changes in symptoms. As the disease progresses, the healthcare
provider might talk about the symptoms of Alzheimer's disease as occurring in moderate
and severe stages.
Common signs of moderate Alzheimer's disease
- Increased memory loss and confusion
- Problems recognizing family and friends
- Continuously repeats stories, favorite words, or motions
- Difficulty carrying out tasks that have multiple steps, like getting dressed
- Lack of concern for hygiene and appearance
Common signs of severe Alzheimer's disease
- Inability to recognize oneself or family
- Inability to communicate
- Lack of control of bowel and bladder
- Groaning, moaning, or grunting
- Needing help with all activities of daily living
If the healthcare provider has prescribed only an AChEI for moderate or severe Alzheimer's
disease, adding NAMENDA XR may help.
In a clinical trial of patients taking AChEIs, adding NAMENDA XR produced benefits
in mental function (also called cognition) and overall patient functioning (also
called global function, which was based on the healthcare provider's assessment
of the patient and interview with the caregiver).
NAMENDA XR has been studied in patients already taking a stable dose of donepezil
(5-10 mg), galantamine (8-24 mg), or rivastigmine (3-12 mg).
There is no evidence that NAMENDA XR or an AChEI prevents or slows the underlying
disease process in patients with Alzheimer's disease.
If your loved one has been diagnosed with moderate Alzheimer's disease and symptoms have progressed
since diagnosis, ask the doctor about adding NAMENDA XR to an AChEI. If your loved one
has started an AChEI, ask about reevaluating your loved one's treatment regimen in about 3 months.
Learn about taking once-daily
Prepare to discuss NAMENDA
XR with your loved one's doctor
*ARICEPT is a registered trademark of Eisai Co., Ltd.
†RAZADYNE is a registered trademark of Johnson & Johnson.
‡EXELON is a registered trademark of Novartis AG Corp.